An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction

Date
2022
Author
Belbaraka, Rhizlane
Mezlini, Amel
Larbaoui, Blaha
Ben Ahmed, Slim
Errihani, Hassan
Alsaleh, Khalid
ÖZGÜROĞLU, MUSTAFA
ÇİÇİN, İRFAN
Goktas, Burce
Yumuk, Perran Fulden
Oukkal, Mohammed
Mahfouf, Hassen
Metadata
Show full item record
Abstract
Objective: This study was designed to investigate treatment satisfaction in patients and Health Care Professionals (HCP) and to evaluate the safety and tolerability of subcutaneous (SC) trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC).
URI
http://hdl.handle.net/20.500.12627/183537
https://avesis.istanbul.edu.tr/api/publication/83fea010-f7f2-4546-b49b-9269e9370b9c/file
https://doi.org/10.4274/ejbh.galenos.2021.2021-9-9
Collections